BridgeBio Pharma
Tracked across 3 events · 54 articles · First seen Jun 11, 2026 · Last active Sep 04, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: BridgeBio Pharma formed a strategic distribution partnership with DKSH to support regulatory evaluation and potential patient access to its transthyretin stabilizer for ATTR-CM in key Asia Pacific markets, leveraging DKSH's commercialization platform.
Jun 11, 2026 · 9 articles
Business
Impact: BridgeBio Pharma is the issuer of the shares being sold in the secondary offering. The company does not receive any proceeds, but the offering diversifies its shareholder base, which may be seen as a positive for long-term ownership stability.
Aug 13, 2026 · 8 articles
Domestic
On August 31, 2026, President Donald Trump announced voluntary drug pricing agreements with nine pharmaceutical companies: Alcon, Astellas Pharma, BeOne Medicines, BridgeBio Pharma, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. These companies agreed…
Impact: BridgeBio Pharma joined the MFN pricing agreement, offering drugs at reduced prices to United States — Medicaid. This may lower U.S. revenue but provides tariff relief and supports patient access.
Aug 18, 2026 · 37 articles
80
BridgeBio Pharma signed drug pricing deal United StatesTrump announces nine new...
ERGEN INTELLIGENCE
Track BridgeBio Pharma live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard